Literature DB >> 15799762

Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.

Nagwa El Amin1, Christian G Giske, Shah Jalal, Berit Keijser, Göran Kronvall, Bengt Wretlind.   

Abstract

Imipenem resistance in Pseudomonas aeruginosa is considered to be associated with loss of the porin OprD combined with activity of chromosomal beta-lactamase (AmpC), while overexpression of multidrug efflux pumps is considered to confer meropenem resistance. Carbapenem resistance can also result from production of metallo-beta-lactamases. Transcription of oprD and efflux pump genes mexB, mexY and mexF was analysed in 23 clinical isolates of P. aeruginosa by quantitative RT-PCR. oprD was sequenced in all, and mexR, regulator of efflux pump MexAB-OprM, in selected isolates. Four isolates that were imipenem susceptible had significant reduction of oprD mRNA and presence of oprD mutations causing frameshift or translational stop. In strains only resistant to imipenem no significant difference in transcription of oprD was observed between low-level and high-level resistant isolates. The differences could not be explained by either pattern of oprD mutations. Increased transcription of mexB generally correlated well with meropenem resistance. One high-level meropenem-resistant isolate showed no significant change in mexB mRNA, but sequencing confirmed presence of a nalB mutation. Furthermore, one meropenem-susceptible isolate showed significant increase in mexB transcription, but no mexR mutations. In summary, our findings indicate that the resistance patterns observed cannot be fully explained by the currently described carbapenem resistance mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799762     DOI: 10.1111/j.1600-0463.2005.apm1130306.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  40 in total

1.  Infrequent finding of metallo-β-lactamase VIM-2 in carbapenem-resistant Pseudomonas aeruginosa strains from Croatia.

Authors:  Sanda Sardelic; Branka Bedenic; Céline Colinon-Dupuich; Stjepan Orhanovic; Zrinka Bosnjak; Vanda Plecko; Benoit Cournoyer; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Urinary tract infection: aetiology and antimicrobial resistance pattern in infants from a tertiary care hospital in northern India.

Authors:  Nirmaljit Kaur; Shweta Sharma; Shalini Malhotra; Preeti Madan; Charoo Hans
Journal:  J Clin Diagn Res       Date:  2014-10-20

3.  Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Authors:  Bartolomé Moyá; Alejandro Beceiro; Gabriel Cabot; Carlos Juan; Laura Zamorano; Sebastián Alberti; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

4.  The effects of active efflux pumps on antibiotic resistance in Pseudomonas aeruginosa.

Authors:  Huseyin Agah Terzi; Canan Kulah; Ihsan Hakkı Ciftci
Journal:  World J Microbiol Biotechnol       Date:  2014-06-26       Impact factor: 3.312

5.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Efflux pumps expression and its association with porin down-regulation and beta-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil.

Authors:  Danilo E Xavier; Renata C Picão; Raquel Girardello; Lorena C C Fehlberg; Ana C Gales
Journal:  BMC Microbiol       Date:  2010-08-12       Impact factor: 3.605

7.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  Persistence of Pseudomonas aeruginosa in a pulmonary nodule with late relapse.

Authors:  S Ronkainen; Y Xie; M Battiwalla; A J Barrett; F Stock; J P Dekker; R L Danner
Journal:  Transpl Infect Dis       Date:  2014-06-26       Impact factor: 2.228

Review 9.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa.

Authors:  S A Dunham; C J McPherson; A A Miller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-23       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.